☰

Wolfgang Sippl

Affiliations: 
Pharmaceutical Chemistry Martin Luther University of Halle-Wittenberg 
Website:
http://pc.pharmazie.uni-halle.de/medchem/sipple/
Google:
"Wolfgang Sippl"
Bio:

http://www.mfu.ac.th/school/science/web/download/anscse14/WSippl_CV.pdf
Wolfgang Sippl is Professor for Medicinal Chemistry and Head of the Department of Pharmaceutical Chemistry at the Martin-Luther-University of Halle-Wittenberg (Germany). He obtained a Ph. D. in Pharmaceutical Chemistry at the University of Düsseldorf in the group of Prof. Dr. Dr. h.c. Hans-Dieter Höltje and was a post-doctoral fellow at the Université Louis-Pasteur in Strasbourg (France) where he worked with Prof. Dr. Camille G. Wermuth. He then took a senior researcher position in Düsseldorf before moving to the University of Halle-Wittenberg as a full professor in 2003. His main interests are focused on computational chemistry and structure-based drug design and the application for identifying novel leads for epigenetic targets.

Mean distance: 13271
 
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Hans-Dieter Höltje grad student 1997 University Düsseldorf
 (Molecular modelling Untersuchungen zum Bindungsverhalten von Histamin H2-und H3-Rezeptor Liganden)

Children

Sign in to add trainee
Suhaib Shekfeh grad student 2009- Martin Luther University of Halle-Wittenberg
Abdurrahman Olgac post-doc 2018-2018 Martin Luther University of Halle-Wittenberg

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Baselious F, Hilscher S, Robaa D, et al. (2024) Comparative Structure-Based Virtual Screening Utilizing Optimized AlphaFold Model Identifies Selective HDAC11 Inhibitor. International Journal of Molecular Sciences. 25
Pannek M, Alhalabi Z, Tomaselli D, et al. (2024) Specific Inhibitors of Mitochondrial Deacylase Sirtuin 4 Endowed with Cellular Activity. Journal of Medicinal Chemistry
Tavares MT, Krüger A, Yan SLR, et al. (2023) 1,3-Diphenylureido hydroxamate as a promising scaffold for generation of potent antimalarial histone deacetylase inhibitors. Scientific Reports. 13: 21006
Baselious F, Robaa D, Sippl W. (2023) Utilization of AlphaFold models for drug discovery: Feasibility and challenges. Histone deacetylase 11 as a case study. Computers in Biology and Medicine. 167: 107700
Abdelsalam M, Zmyslia M, Schmidtkunz K, et al. (2023) Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cells. Archiv Der Pharmazie. e2300536
Sinatra L, Vogelmann A, Friedrich F, et al. (2023) Development of First-in-Class Dual Sirt2/HDAC6 Inhibitors as Molecular Tools for Dual Inhibition of Tubulin Deacetylation. Journal of Medicinal Chemistry. 66: 14787-14814
Bülbül EF, Robaa D, Sun P, et al. (2023) Application of Ligand- and Structure-Based Prediction Models for the Design of Alkylhydrazide-Based HDAC3 Inhibitors as Novel Anti-Cancer Compounds. Pharmaceuticals (Basel, Switzerland). 16
Wimmer S, Hoff K, Martin B, et al. (2022) Synthesis, biological evaluation, and molecular docking studies of aldotetronic acid-based LpxC inhibitors. Bioorganic Chemistry. 131: 106331
Darwish S, Heimburg T, Ridinger J, et al. (2022) Synthesis, Biochemical, and Cellular Evaluation of HDAC6 Targeting Proteolysis Targeting Chimeras. Methods in Molecular Biology (Clifton, N.J.). 2589: 179-193
Abdelsalam M, Ibrahim HS, Krauss L, et al. (2022) Development of Pyrazine-Anilinobenzamides as Histone Deacetylase HDAC1-3 Selective Inhibitors and Biological Testing Against Pancreas Cancer Cell Lines. Methods in Molecular Biology (Clifton, N.J.). 2589: 145-155
See more...